That NWBO did not press that P3 trial was not the question asked. The question was why nobody else would pay NWBO to do so. If DCVax-Prostate really was a better/cheaper Provenge, it would be worth over $1B without question.
That nobody wanted to pay NWBO anything for a P3 ready drug with that upside says it all.
Just like the patent question he asked, no long will ever answer the question.
Not sure about that. More men die of prostate cancer than GBM. It is true that most prostate cancer is indolent but the prevalence is so high that the minority of patients with high risk prostate cancer are still more numerous than GBM patients. High risk prostate cancer is an unmet need and a lethal disease.
Why don’t you educate yourself about the most common cause of death in men and in women in US and also most common cancer in both before posting authoritative statements .
News 
Market Data 
Discover 
